中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (1): 56-59.doi: 10.12144/zgmfskin202201056

• 综述 • 上一篇    下一篇

生物制剂治疗化脓性汗腺炎的研究进展

毛蒙蒙,柏冰雪   

  1. 哈尔滨医科大学附属第二医院皮肤性病科，哈尔滨医科大学，哈尔滨，150001
  • 出版日期:2022-01-15 发布日期:2021-11-01
  • 通讯作者: 柏冰雪，E-mail: bxuebdd@163.com

Update of the biological for treating hidradenitis suppurativa

MAO Mengmeng, BAI Bingxue   

  1. Department of Dermatovenereology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin 150001, China
  • Online:2022-01-15 Published:2021-11-01
  • Contact: BAI Bingxue, E-mail: bxuebdd@163.com

PDF (PC)

340

摘要： 化脓性汗腺炎（HS）是一种慢性炎症性疾病，其发病机制的最新研究为新疗法的开发应用提供了新的思路。多项研究已表明针对参与疾病发展的特定细胞因子的靶向生物制剂对HS的治疗有效。本文就抗IL-17、TNF、IL-1、IL-12/IL-23单克隆抗体、JAK/STAT通路抑制剂、补体C5a抑制剂以及磷酸二酯酶抑制剂对HS的治疗进展进行综述。

关键词: 化脓性汗腺炎, 生物制剂, 单克隆抗体

Abstract: Hidradenitis suppurativa (HS) is a chronic inflammatory disease. The latest research on the pathogenesis of HS has provided new ideas for therapies. A number of studies have shown that targeted biological agents targeting specific cytokines involved in HS are effective. The update of monoclonal antibodies against IL-17, TNF, IL-1, IL-12/IL-23, JAK/STAT pathway inhibitors, complement C5a inhibitors and phosphodiesterase inhibitors in the treatment of HS is reviewed in this paper.

Key words: hidradenitis suppurativa, biological agents, monoclonal antibodies